22-25 April 2010,
Rome, Italy

Like the previous Drug Hypersensitivity Meetings (Bern in 2004, Liverpool in 2006, and Paris in 2008), the DHM4 will bring together international experts with the aim of fostering the exchanges of knowledge in drug hypersensitivity and improving the management of a constantly evolving problem. Numerous international experts from various fields regarding drug hypersensitivity – researchers, clinicians, and representatives of regulatory agencies and pharmaceutical companies, many of whom belonging to the European Network for Drug Allergy (ENDA), the EAACI Interest Group on Drug Hypersensitivity – will be present and will provide an updating on pathogenic mechanisms of drug hypersensitivity reactions, as well as on their diagnosis and prevention.

Main Topics

• Epidemiology of hypersensitivity drug reactions
• Pharmacovigilance
• Pharmacogenetics (genetic tests to prevent allergic reactions to drugs)
• Risk factors for drug hypersensitivity
• Immunotoxicology
• Animal models for systemic drug hypersensitivity
• Basic mechanisms of drug hypersensitivity
• Virus reactivation and drug hypersensitivity / Virus drug interaction
• Latest research on drug hypersensitivity
• Dendritic cells in drug hypersensitivity
• Mastocytosis and drug allergy
• Severe cutaneous reactions
• Internal organ involvement in drug hypersensitivity
• Quality of life in patients with drug hypersensitivity
• In vitro diagnostic tests (serum specific IgE assays, basophil activation test, lymphocyte activation test)
• In vivo diagnostic tests (skin tests, provocation tests)
• Diagnosis and clinical management of hypersensitivity reactions to

- antibiotics (betalactam and non-betalactam)
- nonsteroidal anti-inflammatory drugs
- antineoplastic agents
- contrast media
- muscle relaxants and other perioperative drugs
- biological agents anticonvulsants
- anticoagulants
- new drugs
- additives

Treatment of hypersensitivity drug reactions, especially of the most severe ones. Desensitization or tolerance induction in drug hypersensitivity (protocols for antibiotics, antineoplastic agents, biological agents etc.).

For more information please visit the website http://www.dhm4.net/.